Literature DB >> 22988297

A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma.

Elise Bonvin1, Paola Falletta, Heather Shaw, Veronique Delmas, Colin R Goding.   

Abstract

Deregulation of transcription arising from mutations in key signaling pathways is a hallmark of cancer. In melanoma, the most aggressive and lethal form of skin cancer, the Brn-2 transcription factor (POU3F2) regulates proliferation and invasiveness and lies downstream from mitogen-activated protein kinase (MAPK) and Wnt/β-catenin, two melanoma-associated signaling pathways. In vivo Brn-2 represses expression of the microphthalmia-associated transcription factor, MITF, to drive cells to a more stem cell-like and invasive phenotype. Given the key role of Brn-2 in regulating melanoma biology, understanding the signaling pathways that drive Brn-2 expression is an important issue. Here, we show that inhibition of phosphatidylinositol 3-kinase (PI3K) signaling reduces invasiveness of melanoma cells in culture and strongly inhibits Brn-2 expression. Pax3, a transcription factor regulating melanocyte lineage-specific genes, directly binds and regulates the Brn-2 promoter, and Pax3 expression is also decreased upon PI3K inhibition. Collectively, our results highlight a crucial role for PI3K in regulating Brn-2 and Pax3 expression, reveal a mechanism by which PI3K can regulate invasiveness, and imply that PI3K signaling is a key determinant of melanoma subpopulation diversity. Together with our previous work, the results presented here now place Brn-2 downstream of three melanoma-associated signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22988297      PMCID: PMC3486186          DOI: 10.1128/MCB.01067-12

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  58 in total

Review 1.  The discovery of the microphthalmia locus and its gene, Mitf.

Authors:  Heinz Arnheiter
Journal:  Pigment Cell Melanoma Res       Date:  2010-09-02       Impact factor: 4.693

2.  Overexpression of Akt converts radial growth melanoma to vertical growth melanoma.

Authors:  Baskaran Govindarajan; James E Sligh; Bethaney J Vincent; Meiling Li; Jeffrey A Canter; Brian J Nickoloff; Richard J Rodenburg; Jan A Smeitink; Larry Oberley; Yuping Zhang; Joyce Slingerland; Rebecca S Arnold; J David Lambeth; Cynthia Cohen; Lu Hilenski; Kathy Griendling; Marta Martínez-Diez; José M Cuezva; Jack L Arbiser
Journal:  J Clin Invest       Date:  2007-02-22       Impact factor: 14.808

Review 3.  Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease.

Authors:  Jennifer D Kubic; Kacey P Young; Rebecca S Plummer; Anton E Ludvik; Deborah Lang
Journal:  Pigment Cell Melanoma Res       Date:  2008-12       Impact factor: 4.693

Review 4.  POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumourigenesis.

Authors:  Anthony L Cook; Richard A Sturm
Journal:  Pigment Cell Melanoma Res       Date:  2008-10-22       Impact factor: 4.693

5.  Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells.

Authors:  Jane Goodall; Suzanne Carreira; Laurence Denat; Dominique Kobi; Irwin Davidson; Paolo Nuciforo; Richard A Sturm; Lionel Larue; Colin R Goding
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

Review 6.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions.

Authors:  Jane E Visvader; Geoffrey J Lindeman
Journal:  Nat Rev Cancer       Date:  2008-09-11       Impact factor: 60.716

7.  In vivo switching of human melanoma cells between proliferative and invasive states.

Authors:  Keith S Hoek; Ossia M Eichhoff; Natalie C Schlegel; Udo Döbbeling; Nikita Kobert; Leo Schaerer; Silvio Hemmi; Reinhard Dummer
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

8.  PAX3 expression in primary melanomas and nevi.

Authors:  Rebecca S Plummer; Christopher R Shea; Maria Nelson; Sara K Powell; Diane M Freeman; Colleen P Dan; Deborah Lang
Journal:  Mod Pathol       Date:  2008-03-07       Impact factor: 7.842

9.  Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.

Authors:  David Dankort; David P Curley; Robert A Cartlidge; Betsy Nelson; Anthony N Karnezis; William E Damsky; Mingjian J You; Ronald A DePinho; Martin McMahon; Marcus Bosenberg
Journal:  Nat Genet       Date:  2009-03-12       Impact factor: 38.330

10.  Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.

Authors:  Claudia Wellbrock; Sareena Rana; Hugh Paterson; Helen Pickersgill; Thijn Brummelkamp; Richard Marais
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

View more
  19 in total

Review 1.  The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology.

Authors:  Akinori Kawakami; David E Fisher
Journal:  Lab Invest       Date:  2017-03-06       Impact factor: 5.662

2.  PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma.

Authors:  Jennifer D Kubic; Jason W Lui; Elizabeth C Little; Anton E Ludvik; Sasank Konda; Ravi Salgia; Andrew E Aplin; Deborah Lang
Journal:  J Biol Chem       Date:  2015-07-23       Impact factor: 5.157

3.  NFATc2 is an intrinsic regulator of melanoma dedifferentiation.

Authors:  V Perotti; P Baldassari; A Molla; C Vegetti; I Bersani; A Maurichi; M Santinami; A Anichini; R Mortarini
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

4.  In silico studies of the interaction between BRN2 protein and MORE DNA.

Authors:  Ivan Evangelista do Vale Coelho; Denise Costa Arruda; Alex Gutterres Taranto
Journal:  J Mol Model       Date:  2016-08-27       Impact factor: 1.810

5.  FOXD3 Promotes PAX3 Expression in Melanoma Cells.

Authors:  Jennifer D Kubic; Elizabeth C Little; Rebecca S Kaiser; Kacey P Young; Deborah Lang
Journal:  J Cell Biochem       Date:  2015-09-01       Impact factor: 4.429

Review 6.  Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2017-11-20

7.  BRN2 is a non-canonical melanoma tumor-suppressor.

Authors:  Michael Hamm; Pierre Sohier; Valérie Petit; Jérémy H Raymond; Véronique Delmas; Madeleine Le Coz; Franck Gesbert; Colin Kenny; Zackie Aktary; Marie Pouteaux; Florian Rambow; Alain Sarasin; Nisamanee Charoenchon; Alfonso Bellacosa; Luis Sanchez-Del-Campo; Laura Mosteo; Martin Lauss; Dies Meijer; Eirikur Steingrimsson; Göran B Jönsson; Robert A Cornell; Irwin Davidson; Colin R Goding; Lionel Larue
Journal:  Nat Commun       Date:  2021-06-17       Impact factor: 14.919

8.  PAX3 and ETS1 synergistically activate MET expression in melanoma cells.

Authors:  J D Kubic; E C Little; J W Lui; T Iizuka; D Lang
Journal:  Oncogene       Date:  2014-12-22       Impact factor: 9.867

Review 9.  New insights into signalling-pathway alterations in rhabdomyosarcoma.

Authors:  B Zhu; J K Davie
Journal:  Br J Cancer       Date:  2014-09-11       Impact factor: 7.640

10.  Carcinogenesis of PIK3CA.

Authors:  Sidra German; Hafiz Muhammad Aslam; Shafaq Saleem; Aisha Raees; Tooba Anum; Arsalan Ahmad Alvi; Abdul Haseeb
Journal:  Hered Cancer Clin Pract       Date:  2013-06-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.